DiBianco R
Am J Cardiol. 1987 May 15;59(13):38F-43F. doi: 10.1016/0002-9149(87)90040-3.
Beta-adrenergic blocking agents with various ancillary properties have been found valuable in the management of patients with hypertension, angina pectoris and atrial and ventricular arrhythmias. They are also used to reduce the risk of a subsequent coronary event after a myocardial infarction. In approximately 2 decades, the role of these agents in the patient with angina pectoris has expanded from one primarily involving the adjunctive treatment of the patient refractory to other drugs, to the present, in which beta-adrenergic blockers are the most common prophylactic agent prescribed for this indication.
已发现具有各种辅助特性的β-肾上腺素能阻滞剂在治疗高血压、心绞痛以及房性和室性心律失常患者方面具有重要价值。它们还用于降低心肌梗死后发生后续冠状动脉事件的风险。在大约20年的时间里，这些药物在心绞痛患者中的作用已从主要用于辅助治疗对其他药物无效的患者，扩展到目前的情况，即β-肾上腺素能阻滞剂是针对该适应症最常用的预防性药物。
